Format

Send to

Choose Destination
Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Author information

1
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
2
Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, USA.
3
National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
4
Department of Haematology, CHU Montpellier, Montpellier, France.
5
Department of Haematology, UCLH London, London, UK.
6
Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
7
Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA.
8
Department of Medicine, Universidad San Martin de Porres, Lima, Peru.
9
Catalan Institute of Oncology, German Trias I Pujol Hospital, Badalona, Spain.
10
Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
11
Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australia.

KEYWORDS:

bortezomib; chemotherapy; plasmablastic lymphoma; survival

PMID:
29527667
DOI:
10.1111/bjh.15156

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center